World Hypopara Awareness Day is June 1!
Join us in raising awareness for people living with hypoparathyroidism and share this link.
Advancing peptides for the treatment of rare endocrine and related diseases
We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.
PROGRAMS
Eneboparatide

Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.
Eneboparatide (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.
AZP-3813
AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.
HUMAN GROWTH HORMONE AND EXTRACELLULAR DOMAIN OF ITS RECEPTOR: CRYSTAL STRUCTURE OF THE COMPLEX. de Vos, A.M., Ultsch, M., Kossiakoff, A.A. (1992) Science 255: 306-312. Image created with Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/molva.20181103). RCSB Protein Data Bank, PDB ID: 3HHR.

LEADERSHIP
Our management team has the collective and proven expertise necessary to advance its portfolio of innovative therapies in the clinic.
Press Releases & Recent News
Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA
January 24, 2023
Download a PDF copy of this press release: EN FR Amolyt to advance pre-clinical development of anti-PTHR1 monoclonal antibodies as …
Written by
Dan Hennings
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
January 6, 2023
Download a PDF copy of this press release: EN FR Funds will be used to complete phase 3 clinical development …
Written by
Dan Hennings